Track market-moving stories before they get noisy

AXQ Capital LP grew its stake in shares of Doximity, Inc. (NYSE:DOCS – Free Report) by 1,354.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 177,044 shares of the company’s stock after buying an additional 164,872 shares during the period. AXQ Capital LP owned approximately 0.10% of Doximity worth $3,672,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. Carmignac Gestion lifted its holdings in Doximity by 127.8% during the first quarter. Carmignac Gestion now owns 4,311,997 shares of the company’s stock worth $100,480,000 after acquiring an additional 2,418,971 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Doximity by 3,403.2% during the first quarter. SG Americas Securities LLC now owns 1,408,597 shares of the company’s stock worth $32,820,000 after purchasing an additional 1,368,388 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Doximity by 325,436.6% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,298,891 shares of the company’s stock valued at $57,515,000 after purchasing an additional 1,298,492 shares in the last quarter. Federated Hermes Inc. grew its position in shares of Doximity by 3,422.7% in the 4th quarter. Federated Hermes Inc. now owns 1,249,085 shares of the company’s stock valued at $55,309,000 after purchasing an additional 1,213,627 shares during the period. Finally, Swedbank AB grew its position in shares of Doximity by 1,147.9% in the 1st quarter. Swedbank AB now owns 1,010,559 shares of the company’s stock valued at $23,546,000 after purchasing an additional 929,576 shares during the period. 87.19% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes DOCS has been the topic of a number of research reports. KeyCorp lowered shares of Doximity from an “overweight” rating to a “sector weight” rating in a research note on Thursday, May 14th. Zacks Research upgraded shares of Doximity from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. BMO Capital Markets reaffirmed a “market perform” rating and issued a $30.00 price objective on shares of Doximity in a research report on Friday, August 7th. Wolfe Research raised shares of Doximity to an “outperform” rating in a research note on Thursday, August 13th. Finally, Canaccord Genuity Group set a $36.00 target price on shares of Doximity in a research note on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have given a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $32.43.

Read Our Latest Report on Doximity Insider Buying and Selling at Doximity In related news, Director Kira Wampler sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $24.95, for a total value of $49,900.00. Following the completion of the sale, the director directly owned 19,839 shares in the company, valued at approximately $494,983.05. The trade was a 9.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Siddharth Sitaram sold 2,444 shares of the stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $20.41, for a total value of $49,882.04. Following the sale, the insider directly owned 90,706 shares in the company, valued at $1,851,309.46. This represents a 2.62% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 13,714 shares of company stock valued at $437,251 in the last ninety days. 31.80% of the stock is currently owned by corporate insiders.

Doximity Trading Up 2.6% NYSE DOCS opened at $27.01 on Friday. The firm’s fifty day moving average price is $23.21 and its two-hundred day moving average price is $23.07. Doximity, Inc. has a 1 year low of $17.15 and a 1 year high of $76.51. The firm has a market capitalization of $4.81 billion, a P/E ratio of 31.78, a price-to-earnings-growth ratio of 20.59 and a beta of 1.25.

Doximity (NYSE:DOCS – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.16 by $0.13. The company had revenue of $156.62 million during the quarter. Doximity had a net margin of 25.48% and a return on equity of 18.06%. The business’s revenue was up 7.3% on a year-over-year basis. During the same period last year, the business earned $0.36 EPS. On average, research analysts anticipate that Doximity, Inc. will post 0.74 EPS for the current fiscal year.

Doximity Company Profile (Free Report)

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.

Featured Articles Five stocks we like better than Doximity The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now Dropping the Dough: Yum! Brands Strategically Trims the Fat These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern

Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.

Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced new data indicating that physicians are finding an unexpected source of optimism in AI. Rather than viewing the technology as a threat, nearly a quarter expect it to increase their total compensation within the next year, and two-thirds believe staying current with AI will give them a meaningful earnings edge over peers who don't.

The findings are part of Doximity’s annual Physician Compensation Report, which also shows that the physician shortage continues to weigh heavily on daily practice, with 76% of physicians saying it compromised the quality of care they were able to provide in the past year. That strain is showing up in a growing desire to leave medicine altogether as physicians report being overworked, considering a career change, or eyeing early retirement.

“Physicians go into medicine because they’re passionate about helping people,” said Amit Phull, MD, chief medical officer at Doximity. “Then the job compromises that mission. Admin burden. Extreme hours. A system that doesn’t feel built for them anymore. So it’s no surprise they're looking at AI as leverage, not a threat. Our job at Doximity is simple: give them time back through AI that helps them be more productive and provide better care for their patients.”

Report Highlights

Physicians See AI Fluency as the Next Career Advantage

Rather than fearing displacement, physicians are looking to capitalize: 23% expect AI to increase their total compensation within the next 12 months.67% believe physicians who stay current with AI tools will have a meaningful earnings advantage over colleagues who don't adopt them in the next 12 months.AI Is the New Professional Currency

At least 39% of physicians surveyed said that AI proficiency is a factor in hiring and promotion decisions for their specialty, including 15% who described it as either a “major” or “moderate” factor.Shortage Still Straining Physicians Fuels Career-Exit Intent

85% of physicians said the physician shortage has already affected their clinical practice.76% said the shortage and other systemic pressures compromised the quality of care they provided in the past 12 months.In a June 2026 Doximity poll of more than 600 physicians, 82% reported being overworked.Among overworked physicians, 66% are considering a career change, including 46% eyeing early retirement, up from 34%.Broader Compensation Trends

Average physician compensation rose 2% in 2025, down from 3.7% growth the year prior, continuing a trend of moderating pay growth.The gender pay gap held steady at 26% for the second consecutive year, with men earning a nominal $122,276 more than women on average.The pay gap between primary care physicians and specialists widened this year: surgical specialists now earn 90.1% more than primary care physicians, up from 87.3% in 2024.With over 85% of U.S. physicians as members, Doximity brings together one of the nation’s largest physician compensation datasets with workforce surveys, recruiting activity, staffing trends, and insights into AI adoption. The 2026 Physician Compensation Report features new survey findings from June 2026 on how AI is changing physician careers and pay, along with salary data from Doximity’s compensation dataset of more than 23,000 responses collected in 2025.

Read the full 2026 Physician Compensation Report here.

About Doximity

Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company’s network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. With new AI-powered clinical reference and search capabilities, Doximity also helps doctors access trusted, peer-reviewed information and medical literature. Doximity’s mission is to help doctors be more productive so they can provide better care for their patients.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260825863688/en/

Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

On August 27, 2026, Doximity Inc DOCS shares rose 3.4% to a current price of $25.59, reflecting a significant shift amidst a 52-week range of $17.15 to $76.51. This price movement comes after a challenging year where the stock has experienced a -62.4% decline.

GF Value™ verdict: Current price of $25.59 is 43.8% below the GF Value estimate of $45.50. GF Score™ of 82/100 indicates a strong overall assessment. Notable signal: Insider activity shows $4.7M in sales over the past year with no buying. Is DOCS Overvalued or Undervalued? According to the GF Value™, Doximity Inc is currently significantly undervalued, with a fair value estimate of $45.50 compared to its current price of $25.59. This indicates a margin of safety of approximately 43.8%, suggesting that the stock is trading at a discount relative to its intrinsic value. GF Value™ is GuruFocus' proprietary estimate of a stock's true worth based on historical trading multiples, past business growth, and future performance projections. The undervaluation presents an opportunity for potential investors, though it is essential to consider market conditions and other risk factors that could influence the stock's actual performance.

How Does DOCS's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 30.1x 50.2x Forward P/E 18.9x N/A Currently, Doximity's P/E ratio of 30.1x is significantly below its 5-year median of 50.2x, indicating that the stock is trading at a lower valuation compared to its historical performance. The forward P/E of 18.9x further supports the notion that the stock is undervalued, aligning with the GF Value™ assessment.

What Does DOCS's GF Score™ Tell Us? The GF Score™ evaluates a company's financial strength, profitability, growth potential, valuation, and momentum. Doximity's score of 82/100 reflects a robust overall financial health, with notable strengths in profitability and growth, both scoring 9/10. However, its valuation rank is relatively weak at 2/10, indicating that the market may not fully recognize its potential value at this time.

Metric Rating GF Score™ 82 Financial Strength 8/10 Profitability 9/10 Growth 9/10 Valuation 2/10 Momentum 4/10 Overall, the strong profitability and growth scores suggest that Doximity has solid fundamentals and growth prospects, while the low valuation rank indicates that the stock may be undervalued in the current market landscape. Investors might view this as a compelling opportunity to consider the stock further.

What Are Gurus and Insiders Doing with DOCS? Currently, 6 gurus hold Doximity's stock, with 4 adding to their positions and 3 trimming their stakes in recent quarters. This activity indicates a mixed sentiment among institutional investors, which can often signal confidence in the company’s future performance. However, it is worth noting that insiders have sold $4.7 million worth of shares in the past 12 months without any buying activity. This trend may raise some concerns about insider confidence in the stock's future trajectory.

What This Means for Investors Based on the GF Value™ assessment, Doximity Inc appears to be significantly undervalued at its current price of $25.59 compared to the estimated fair value of $45.50. While this presents a potential opportunity for investors, the selling pressure from insiders and the overall market conditions should be considered before making investment decisions. For more detailed insights, visit the Doximity Inc DOCS stock page for additional analysis.

Frequently Asked Questions What is DOCS's GF Score™?

Doximity has a GF Score™ of 82/100, indicating a strong overall assessment of the company's financial health and potential for future growth.

Is DOCS overvalued or undervalued?

Doximity is currently undervalued, with a GF Value™ of $45.50, suggesting significant upside potential from the current price of $25.59.

What is DOCS's P/E ratio?

Doximity's P/E ratio stands at 30.1x, which is considerably lower than its 5-year median of 50.2x, indicating a potential undervaluation of the stock.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Disclosures I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

Key Takeaways Doximity's AI Search is opening a new commercial growth avenue across more than two dozen programs.Clinical AI adoption is rising, with active workflow prescribers up more than 30% year over year.Higher AI compute costs are pressuring margins as pharma advertising budgets remain tight. Doximity (DOCS - Free Report) is entering a pivotal phase as it accelerates investments in artificial intelligence to expand beyond its core physician engagement platform. While robust physician adoption, growing enterprise AI deployments and exceptional cash generation strengthen its long-term outlook, a sluggish pharma advertising market, rising AI investments and commercialization risks could temper near-term financial performance.

Shares of this Zacks Rank #3 (Hold) company have lost 42.8% year to date compared with the industry's 15.5% decline. The S&P 500 Index has risen 11.8% during this period.

Doximity, with a market capitalization of $4.51 billion, is a global specialty medical device company.

Image Source: Zacks Investment Research

DOCS’ bottom line is estimated to improve 1.7% over the next five years. Its earnings beat estimates in two of the trailing four quarters and missed twice, delivering an average surprise of 3.13%.

What's Driving DOCS’ Performance?AI Search Is Opening a New Commercial Growth Avenue: Doximity's AI Search business is emerging as a potentially significant incremental revenue stream, with the company already onboarding its first cohort across more than two dozen programs. Management said new AI Search contracts are driving the increase in fiscal 2027 revenue guidance, with most contracted revenues expected to be recognized in the third quarter.

The product is helping Doximity access higher-level decision-makers and innovation budgets at pharmaceutical companies, expanding its commercial relationships beyond traditional digital marketing. Management also noted that AI Search currently generates more than 10 times the revenue per search relative to its cost, indicating attractive unit economics that could improve further as utilization scales.

Rapid Clinical AI Adoption Strengthens Competitive Position: Doximity is gaining meaningful traction in clinical AI, with quarterly active workflow prescribers increasing more than 30% year over year and nearly half of them using AI tools. AI prompt volume rose more than 25% sequentially, while AI Scribe users increased sharply. The company's Ask platform also ranked strongly in the independent NOHARM study, posting a 4.8% clinical error rate compared with 13.6% for Anthropic's best-performing model cited by management. The combination of physician engagement, drug-reference integration and more than 12,000 physician PeerCheck editors could strengthen trust among hospitals and clinicians, providing an important competitive advantage as healthcare AI adoption accelerates.

Expanding Health-System Adoption Creates Opportunity: Doximity's enterprise AI footprint is expanding rapidly, with 165 signed health-system AI clients, including eight top Honor Roll hospitals. Recent wins with major academic institutions demonstrate that Doximity is increasingly becoming part of institutional clinical workflows rather than simply serving as a physician networking platform.

Management believes the market is moving toward greater emphasis on privacy, risk management and clinical accuracy, areas where Doximity believes its physician-reviewed AI architecture provides differentiation. The growing adoption of AI Search, Ask and Scribe also creates opportunities to cross-sell multiple products within the same health system, potentially increasing customer lifetime value and reducing dependence on pharmaceutical advertising over time.

What’s Weighing on DOCS StockAI Investment is Compressing Margins: Doximity's transition toward AI is creating a meaningful near-term profitability trade-off. Adjusted gross margin declined 300 basis points year over year to 88% in the first quarter, primarily because of higher AI compute costs required to support stronger-than-expected clinician usage.

Management expects elevated AI spending to continue throughout fiscal 2027, with adjusted EBITDA guidance implying a 47% margin, below the 48% achieved in the first quarter. Approximately 90% of incremental AI expenses will support the clinical AI suite and be recognized in cost of revenues. Although management expects eventual efficiency improvements, the timing mismatch between investment and monetization could constrain earnings growth in the near term.

Pharmaceutical Advertising Budgets Remain Tight: Despite improving customer engagement, Doximity continues to operate in a relatively cautious pharmaceutical spending environment. Although management characterized the overall buying environment as stabilizing but pressure still remains. Management maintains expectations for mid-single-digit growth in the HCP digital marketing market.

Doximity's full-year revenue guidance of $671-$681 million represents only 5% growth at the midpoint, suggesting that the underlying core business remains relatively subdued. Although AI Search is helping the company access innovation and analytics budgets, traditional pharmaceutical marketing remains sensitive to budget cycles and shorter-term commitments. Consequently, slower recovery in pharma spending could limit growth while the company simultaneously increases AI-related expenses.

Customer Concentration and Contract Structure Create Uncertainty: Doximity's strong relationships with large customers also create concentration risk. The company’s 127 pharma and hospital customers generating more than $500,000 annually accounted for 83% of total revenues, while its top 20 customers achieved 112% net revenue retention. Although these figures demonstrate strong customer economics, reliance on a relatively concentrated group of large accounts makes revenues sensitive to changes in pharmaceutical budgets and individual customer spending decisions.

Management also noted that AI Search initially launched with conservative inventory caps and shorter three- to four-month commitments, highlighting that the new revenue stream is yet to establish long-duration contract visibility. Larger, longer contracts during the upcoming upfront season will be key to improving predictability.

Estimate TrendThe Zacks Consensus Estimate for fiscal 2027 revenues is pegged at $675.7 million, implying growth of 4.8% from the year-ago reported figure. The consensus mark for adjusted EPS is pinned at $1.33, indicating a decline of 12.5% from the previous year’s recorded level.

In the past 30 days, DOCS’ earnings estimate for fiscal 2027 has declined 7 cents.

Stocks to ConsiderSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

Matthew Sonefeldt, the chief financial officer of Doximity, Inc. (DOCS -1.13%), reported a non-discretionary disposition of 15,311 shares of Class A Common Stock on August 15, according to an SEC Form 4 filing.

Transaction summaryMetricValueShares sold (direct)15,311Transaction value$380,000Post-transaction shares (directly held)486,238Post-transaction value$12.1 millionTransaction value based on SEC Form 4 weighted average sale price ($24.80).

Key questionsDoes this transaction reflect a shift in the executive's outlook on the firm?
The disposition was a non-discretionary event triggered by tax liabilities linked to equity compensation vesting. Because the shares were withheld by the company to cover these obligations rather than sold in an open-market discretionary trade, the move does not provide a signal regarding the CFO's view on the stock's valuation.What is the scale of the remaining incentive alignment?
Sonefeldt maintains a significant equity interest in the company, holding 486,238 shares directly. This position represents a substantial capital commitment of $12.1 million based on the market close price of $24.80 on August 14.What are the core fundamentals of the business at the time of this filing?
The company operates a digital platform for healthcare practitioners, generating trailing 12-month revenue of $655.6 million and net income of $167.0 million. Its primary client base includes pharmaceutical companies and healthcare organizations that utilize the platform for peer networking and remote consultations.Company OverviewMetricValueShare Price (as of market close 2026-08-14)$24.80Market Capitalization$4.6 billionRevenue (TTM)$655.6 millionNet Income (TTM)$167.0 millionCompany SnapshotDoximity operates a cloud-hosted digital platform that provides healthcare practitioners with specialized tools for peer connectivity, patient care coordination, remote consultations, medical research access, and professional development.The company generates revenue through subscription-based services and licensing arrangements with pharmaceutical companies and healthcare organizations that utilize the platform to engage with medical professionals.The primary customer base consists of pharmaceutical companies seeking to reach physicians and healthcare organizations seeking to optimize clinical workflows and practitioner engagement across the United States healthcare system.Doximity is a leading digital health platform serving the U.S. healthcare practitioner community with approximately 880 employees and a market capitalization of $4.6 billion. The company has achieved substantial profitability with TTM net income of $167.0 million on revenue of $655.6 million, demonstrating strong unit economics and operational efficiency. Doximity's competitive advantage derives from its comprehensive practitioner network, integrated suite of clinical and professional tools, and established relationships with pharmaceutical and healthcare organization customers.

What this transaction means for investorsSonefeldt has been Doximity's CFO for roughly one quarter as of lastweek, which makes this the first tranche of a new hire's equity vesting and the tax bill that comes with it. Three other insiders had the same thing happen the same day, so the filing itself isn't what's worth lingering on.

The more useful thing about Sonefeldt is what he keeps talking about. On the August 6 call he returned again and again to LinkedIn, where he worked before, and to how its ad business only got enormous after buying shifted to auctions over many years. He was careful to say Doximity isn't unveiling that this year. Instead, this year is a lot less tidy for Doximity. Revenue rose 7% to $156.6 million, but the September quarter is guided to $170 million to $171 million, roughly 1% growth at the midpoint. Sonefeldt said on the same call that "the overall pharma spending environment remains tight," which sits awkwardly next to a raised full-year outlook. AI compute costs pulled gross margin to 87.5% from 91.2%, and adjusted EBITDA slipped 6% to $74.8 million while the company spent $91.6 million buying back stock. His own explanation for the weak growth is timing. The fiscal third quarter, when the AI search revenue lands, as the firm noted on the earnings call, is where that gets tested.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Doximity. The Motley Fool has a disclosure policy.

Chief Accounting Officer Siddharth Sitaram disposed of 5,652 shares of Doximity, Inc. (DOCS -1.13%) for a total value of $140,400 on August 13 and August 15, according to a recent SEC Form 4 filing.

Transaction summaryMetricValueTransaction value$140,400Shares sold5,652Post-transaction shares (directly held)93,122Post-transaction value$2.31 millionTransaction value based on SEC Form 4 weighted average sale price ($24.84).

Key questionsWhat was the primary driver of this transaction?
The activity was non-discretionary and focused on tax management, consisting of 3,882 shares withheld by the issuer to cover restricted stock unit vesting and 1,770 shares sold under a Rule 10b5-1 plan to satisfy tax obligations from an option exercise.What is the insider's remaining equity position in the company?
Sitaram maintains direct ownership of 93,122 shares and also holds 59,000 derivative securities.How has the company performed financially as of the transaction date?
Doximity reported trailing 12-month revenue of $655.6 million and net income of $167.0 million, with a market capitalization of $4.6 billion as of the August 14 market close.Company OverviewMetricValueShare Price (as of market close 2026-08-14)$24.80Market Capitalization$4.6 billionRevenue (TTM)$655.6 millionNet Income (TTM)$167.0 millionCompany SnapshotDoximity operates a cloud-hosted digital platform that provides healthcare practitioners with specialized tools for peer connectivity, patient care coordination, remote consultations, access to medical research, and professional development.The company generates revenue through subscription-based services and licensing arrangements with pharmaceutical companies and healthcare organizations that utilize the platform to engage with medical professionals.The primary customer base consists of pharmaceutical companies seeking to reach physicians and healthcare organizations seeking to optimize clinical workflows and practitioner engagement across the United States healthcare system.Doximity is a leading digital health platform serving the U.S. healthcare practitioner community with approximately 880 employees and a market capitalization of $4.6 billion. The company has achieved substantial profitability with TTM net income of $167.0 million on revenue of $655.6 million, demonstrating strong unit economics and operational efficiency. Doximity's competitive advantage derives from its comprehensive practitioner network, integrated suite of clinical and professional tools, and established relationships with pharmaceutical and healthcare organization customers.

Sitaram did a version of this in mid-July too, exercising a slice of the same $4.12 options and selling just enough to cover what he owed. August was effectively the same again with RSU withholding stacked on top, so this certainly seems routine.

The interesting part is that executive equity has stopped being a footnote in Doximity's actual results. The GAAP effective tax rate ran about 40% in the June quarter against 17% a year earlier, which CFO Matt Sonefeldt tied on the August 6 call to how equity compensation is taxed. That's a meaningful chunk of why GAAP earnings came in at $0.13 a share versus $0.27, while the non-GAAP number was $0.29. The gap between those two figures is wider than usual, and it isn't closing this year.

Meanwhile, Doximity didn't recognize AI search revenue in the June quarter, though the compute costs behind the usage were already in cost of revenue, dragging gross margin to 87.5% from 91.2%. Co-founder and CEO Jeff Tangney said on the call that "we're earning more than 10x per search in revenue than it cost us." That's attractive economics despite a revenue base of zero so far. Next quarter will look to change that.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Doximity. The Motley Fool has a disclosure policy.

Doximity (DOCS), a digital platform for US medical professionals, rose 0.46% premarket after Truist Securities raised its price target to $24 from $19 and reite

Shares of Doximity (DOCS +32.62%) surged on Friday after management highlighted the remarkable returns it was beginning to realize on its artificial intelligence (AI) investments.

Image source: Getty Images.

Q1 results were just part of the story Doximity's revenue rose 7% year over year to $156.6 million in its fiscal 2027 first quarter, which ended on June 30.

Yet its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) fell 6% to $74.8 million. The digital networking, news, and telehealth platform for healthcare professionals is spending aggressively to develop its AI tools.

Those investments are beginning to pay off in a big way, according to CEO Jeff Tangney.

Today's Change

(

32.62

%) $

6.74

Current Price

$

27.40

Leaning into AI In an independent study of 24 clinical AI models, the company's AI assistant, Doximity Ask, was the top-performing U.S.-based model with the lowest clinical error rates and the highest safety ratings. Notably, Doximity Ask had significantly lower error rates than Anthropic's best model, Fable 5.

This superior performance is leading to sharply higher usage of Doximity's AI offerings.

"AI prompt volume was up more than 25% quarter-on-quarter, while our AI Scribe note-taking users grew a whopping 10x this July over prior," Tangney said during a conference call with analysts.

But what really caught investors' attention were Tangney's comments regarding the profit potential of Doximity's AI tools.

In terms of the economics of the usage, it's early days on our AI Search product, but I can tell you we're earning more than 10 times per search in revenue than it costs us to run that today.

10x certainly has a nice ring to it. And Tangney indicated that the returns would likely get even better from there.

Over time, we probably expect the overall AI cost, if anything, go down as models get more efficient.

Tangney's comments painted a picture of a lucrative, AI-driven future for Doximity, and investors bid up its shares as they rushed to grab a piece of it.

"We are leaning in as we see a once-in-a-generation opportunity to build the new AI age of medicine," Tangney said.

Doximity is the Facebook and LinkedIn of the Medical CommunityDoximity NYSE: DOCS reported fiscal 2027 first-quarter revenue of $157 million, up 7% from a year earlier, as the company cited improving demand from pharmaceutical and hospital customers and increased engagement with its clinical artificial intelligence tools.

Adjusted EBITDA totaled $75 million, representing a 48% margin. CEO and Co-Founder Jeff Tangney said revenue and adjusted EBITDA exceeded the high end of the company’s guidance by 3% and 8%, respectively. Doximity also raised its full-year revenue outlook by $6 million while continuing to increase spending on AI infrastructure, safety and product development.

Get Doximity alerts:

AI usage and clinical-study results Doximity is an Overlooked Medical Ecosystem AI Play Tangney said Doximity’s clinical AI products reached record usage levels during the quarter. Quarterly active workflow prescribers increased more than 30% year over year, with nearly half using the company’s AI tools in the period. AI prompt volume grew more than 25% sequentially, while usage of Doximity’s AI Scribe note-taking product rose 10-fold in July compared with the prior year, according to the company.

The CEO also highlighted the NOHARM study, an independent evaluation of 24 clinical AI models across 1,100 real-world patient cases conducted by researchers from Stanford and Harvard. Tangney said Doximity Ask had the lowest clinical error rate and highest safety rating among U.S. models in the study. He said Doximity’s model recorded a 4.8% error rate, compared with 13.6% for Anthropic’s Fable 5 model.

Doximity Stock is an Interesting Healthcare PlayDoximity attributed its results to a built-in drug reference that it said is expert-verified for drug dosing and interactions, as well as more than 12,000 physician PeerCheck editors who review and refine AI outputs. Tangney said hospitals are increasingly focused on privacy, data protection and the potential liability associated with clinical AI outputs.

The company has signed 165 health-system AI clients, including eight hospitals on the nation’s honor roll, Tangney said. Recent health-system wins included Northwestern, Penn Medicine and the University of Michigan. Doximity said all 165 clients are live in the sense that they have privacy agreements in place and their physicians can use its AI tools, though systems are at varying stages of electronic-health-record integration.

AI Search supports commercial activity Doximity launched AI Search in late April and said the product is generating higher engagement with pharmaceutical customers. CFO Matt Sonefeldt said the company did not recognize AI Search revenue during the first quarter, but it has onboarded an initial cohort of customers across more than two dozen programs. The majority of contracted AI Search revenue to date is expected to be recognized in the fiscal third quarter.

Sonefeldt said AI Search has helped Doximity access innovation, insights-and-analytics, and search-related budgets at pharmaceutical companies, although the broader pharmaceutical spending environment remains tight. He described the environment as more stable than in prior periods.

During the call, executives said early AI Search contracts were intentionally structured with conservative inventory caps and shorter commitments of three to four months as the company protected the physician user experience and gathered customer feedback. As Doximity enters its annual upfront selling season, it expects to pursue larger and longer contracts, expand inventory across therapeutic categories, and offer more purchasing options, including category, keyword and target-list approaches.

Tangney said Doximity is currently generating more than 10 times as much revenue per AI Search query as it costs to run the service. He added that the company expects the cost of AI models to decline over time as models become more efficient. Sonefeldt said Doximity sees opportunities to improve efficiency through model optimization, capacity management, forecasting and internally developed AI tools.

The company said its AI products can also support its established pharmaceutical marketing offerings. Tangney said insights from AI Search, such as physicians’ questions about drug side effects or dosing conversions, can inform follow-up engagement through Doximity’s telehealth and other platform products.

Financial performance and customer metrics Doximity said revenue growth was supported by pharmaceutical and hospital customers, particularly larger accounts. The company had 127 pharmaceutical and hospital customers generating more than $500,000 in trailing-12-month subscription revenue, up 7% from a year earlier. Those customers represented 83% of total revenue.

Top 20 customer net revenue retention was 112%. Overall trailing-12-month net revenue retention was 107%. Non-GAAP gross margin was 88%, compared with 91% a year earlier. GAAP earnings per share were $0.13, while non-GAAP earnings per share were $0.29. Free cash flow was $40 million, which Doximity attributed in part to normal collection-timing variability. The company ended the quarter with $688 million in cash equivalents and marketable securities and no debt. It repurchased $92 million of shares during the quarter and had roughly $400 million remaining under its repurchase authorization as of June 30.

Outlook reflects additional AI investment For the fiscal second quarter, Doximity forecast revenue of $170 million to $171 million, representing 1% year-over-year growth at the midpoint. The company said the growth rate reflects a difficult comparison with the prior year’s 23% growth and only modest expected AI Search revenue in the second quarter.

For fiscal 2027, Doximity raised its revenue outlook to $671 million to $681 million, representing 5% growth at the midpoint. The higher outlook reflects first-quarter outperformance, a modest incremental increase, a more stable pharmaceutical budget environment, increased customer interaction and an expanding AI commercial pipeline, Sonefeldt said.

Doximity expects second-quarter adjusted EBITDA of $80.5 million to $81.5 million, or a 48% margin at the midpoint. Full-year adjusted EBITDA is projected at $309 million to $329 million, or a 47% margin at the midpoint.

The company said approximately 90% of its AI-related spending will support rising demand for its clinical AI suite and will be recognized in cost of revenue. As a result, Doximity expects gross margins to remain in the mid-to-high-80% range during fiscal 2027.

About Doximity (NYSE:DOCS)Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Doximity Right Now?Before you consider Doximity, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.

While Doximity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Key Takeaways Doximity's Q1 revenues rose 7.3% to $156.6 million, while adjusted EPS fell 19.4% to 29 cents.Higher AI spending and operating costs cut DOCS' adjusted operating margin by 720 bps to 46.2%.Doximity raised fiscal 2027 revenue guidance to $671-$681 million on stronger AI momentum. Doximity, Inc. (DOCS - Free Report) delivered adjusted earnings per share (EPS) of 29 cents in the first quarter of fiscal 2027, down 19.4% year over year. The figure missed the Zacks Consensus Estimate by 3.3%.

GAAP EPS for the quarter was 13 cents, reflecting a downtick of 51.8% from the year-ago figure.

The year-over-year decline in earnings primarily reflected higher AI-related investments and operating expenses, which pressured profitability despite revenue growth.

DOCS’ Q1 Revenues in DetailDoximity registered revenues of $156.6 million in the fiscal first quarter, up 7.3% year over year. The figure surpassed the Zacks Consensus Estimate by 3.2%.

Revenue growth was supported by solid performance across pharma and hospital customers. The company’s net revenue retention rate was 107%, while 127 customers generated more than $500,000 in trailing 12-month subscription revenues, up 7% year over year. These large customers accounted for 83% of total revenues.

Shares of the company surged 73.5% during yesterday’s after-hours trading. Year to date, the stock has declined 53.3% compared with the industry’s fall of 6.4%. However, the broader S&P 500 Index has increased 12.5% in the same time frame.

Image Source: Zacks Investment Research

Doximity's AI Investment Pressures Q1 MarginsIn the quarter under review, Doximity’s adjusted gross profit rose 3% year over year to $137.1 million. However, the adjusted gross margin contracted 370 basis points (bps) to 87.5%.

Sales and marketing expenses increased 23.9% year over year to $45.0 million, while research and development expenses rose 43.6% to $38.5 million. General and administrative expenses increased 26.7% year over year to $15.8 million. Total operating expenses of $99.3 million rose 31.3% year over year.

Management said higher-than-expected clinician AI usage drove additional compute spending, while merit increases, internal AI usage and brand marketing lifted operating costs.

The adjusted operating profit totaled $72.4 million, reflecting a 7.1% decline from the prior-year quarter. The adjusted operating margin in the fiscal first quarter contracted 720 bps to 46.2%.

DOCS' Financial PositionDoximity exited first-quarter fiscal 2027 with cash and cash equivalents of $273.6 million compared with $219.2 million at the end of fiscal 2026, with no debt on its balance sheet. The company repurchased $91.6 million of common stock during the quarter, with $400.9 million remaining under its authorized repurchase program at June 30, 2026.

Net cash provided by operating activities at the end of first-quarter fiscal 2027 was $42 million compared with $62.1 million a year ago. Free cash flow declined 34.1% year over year to $39.6 million.

Management attributed the weaker cash generation partly to normal collection timing, including a $33.3 million increase in accounts receivable.

Doximity’s Q2 & FY27 OutlookDoximity has initiated its financial outlook for the fiscal second quarter and raised the full-year guidance for fiscal 2027.

For the second quarter of fiscal 2027, Doximity expects revenues of $170 million to $171 million. The Zacks Consensus Estimate for revenues is pegged at $168 million.

For fiscal 2027, the company raised its revenue guidance to $671 million-$681 million from $664 million-$676 million. The Zacks Consensus Estimate for revenues is pegged at $670.2 million.

Management cited a more stable pharma budget environment, higher customer interaction velocity and a growing AI commercial pipeline as supporting the stronger outlook.

Doximity’s AI Adoption and Commercial MomentumDoximity exited the first quarter of fiscal 2027 with mixed results, wherein earnings missed while revenues surpassed the Zacks Consensus Estimate. Top-line growth was supported by solid pharma and hospital demand and accelerating AI adoption. However, increased AI investments weighed on margins during the quarter.

Workflow engagement remained strong, with quarterly active prescribers growing more than 30% year over year to record levels. Nearly half of these prescribers used the company’s AI tools, while AI prompt volumes increased more than 25% sequentially. Doximity Ask also emerged as the top-performing U.S.-based clinical AI model in the independent NOHARM benchmark, supported by a built-in drug reference and more than 12,000 physician PeerCheck editors.

Doximity expanded its enterprise AI footprint to 165 signed health-system clients, including eight top Honor Roll hospitals, with recent wins including Northwestern, Penn Medicine and the University of Michigan. Scribe adoption continued to accelerate, with users increasing 10-fold in July.

On the commercial front, AI Search, launched in late April, increased pharma customer engagement. The company onboarded its initial cohort across more than two dozen programs and is building a pipeline for the remainder of fiscal 2027 and beyond. Management expects most AI Search revenues contracted to date to be recognized in the fiscal third quarter. New AI Search contracts also contributed to the company’s raised full-year revenue outlook.

Going forward, Doximity intends to increase investments in its clinical AI suite to capitalize on rising physician usage and commercial demand. Management remains focused on expanding AI Search monetization, strengthening health-system adoption and leveraging its broad physician network to drive long-term growth across pharma and workflow solutions.

DOCS’ Zacks Rank & Key PicksDoximity currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , The Cooper Companies (COO - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank of 2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

West Pharmaceutical reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

West Pharmaceutical has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.40%.

The Cooper Companies reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10.00%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

The Cooper Companies has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.80%.

Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.

Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.27%.

While one analyst thinks Doximity has a compelling AI opportunity, another worries that the company could cannibalize its core business of medical networking.

Doximity DOCS stock as much as doubled on Friday morning after the digital platform for health care professionals posted a solid Q1 sales beat and issued seemingly impressive full-year guidance.

Still, a closer look under the hood suggests these explosive gains are built on a fragile foundation, and the company might just end up paring them back in the days ahead.

In fact, Doximity shares have already reversed a huge chunk of their intraday gains, now up some 33% versus their previous close.

In the earnings release, Doximity’s management framed the quarter as a “reacceleration”.

However, total revenue came in up just 7% year-over-year to $156.6 million. For a digital health platform trading at premium software multiples post-rally, single-digit organic revenue growth is relatively weak.

Its core advertising business from pharmaceutical clients remains constrained due to “tightening” healthcare marketing budgets, meaning true acceleration has yet to materialize in reported sales.

DOCS shares soared primarily on raised FY27 revenue, but the math may not be as bullish as the price action suggests.

The company raised its full-year outlook by $6 million ($671 million to $681 million) – and it beat Q1 revenue estimated by $4.9 million ($156.6 million vs. $151.2 million expected).

What this means is: management passed through the first-quarter outperformance to the full-year target while keeping back-half expectations almost unchanged.

Furthermore, Q2 revenue guidance ($170 million to $171 million) came in essentially in line with the consensus ($171.1 million), offering zero upside surprise for the current quarter.

What’s also worth mentioning is that much of the commentary driving Doximity’s stock price rally centered on its AI Search tool.

Yet, the filing actually revealed key friction points as well.

For starters, management said no revenue from the new artificial intelligence tools was recognized in Q1 – with CFO Matthew Sonefeldt adding that “higher-than-expected” AI usage will require expanding AI infrastructure investments in FY2027.

This could prove bearish as computing costs for clinical LLM queries could erode DOCS’s exciting 48% adjusted EBITDA margins as adoption scales.

Finally, it’s reasonable to take profit in DOCS stock because the firm’s net revenue retention rate, a key metric measuring how much existing clients expand their spending, sat at 107% on a trailing 12-month basis.

Even among its top 20 largest clients, NRR was 112% - well below the 115% to 120% that premium SaaS and enterprise health platforms typically target.

This means upselling existing pharmaceutical brands and hospital networks remains sluggish.

Put all of it together with Doximity’s adjusted EPS of $0.29 in Q1, which missed the consensus set at $0.30, and the rally immediately starts appearing like an opportunity to trim.

Shares of medical platform Doximity more than doubled at one point in overnight trading Friday after some bold comments on the margin for its new AI search tool.

CEO Jeffrey Tangney said the product brings in 10 times what it costs to run.

"It's early days on our AI search product, but I can tell you we're earning more than 10 times per search in revenue than it costs," he said on Thursday during the company's first-quarter fiscal 2027 earnings call.

"Over time, we probably expect the overall AI cost, if anything, [to] go down as models get more efficient, so we feel good about the unit economics there," Tangney added.

Doximity shares were up more than 130% in premarket trading before settling down a bit as the market opened officially. The shares were last up 59%.

Doximity, 1 day

Analysts think these spectacular returns are not yet baked into the company's already solid financials. Doximity reported first-quarter revenues of $156.6 million and adjusted EBITDA of $74.8 million, both of which were above consensus estimates.

The company also raised its full year revenue guidance range up by $6 million, or 5%, to between $671 million and $681 million -- but the huge AI profitability potential is likely not a part of that boosted forecast, analysts said.

"The FY27 raise (which is mostly comprised of the F1Q27 beat) does not reflect a significant contribution from the expanding AI commercial pipeline described on the earning call and in callbacks," Jessica Tassan at Piper Sandler wrote to clients in a Friday note.

Tassan said she thought that management is taking a "conservative approach" to AI search revenue in its FY27 outlook.

Shares of Doximity, which sported a market value of $3.7 billion before Friday's surge, were down 50% for the year before the results.

Short squeezeCEO Tangney suggested that the AI search is resulting in not only higher profitability but also a larger addressable market. 

"Frankly, the [total addressable market] that this unlocks for us within health, within pharma has been a real surprise and upside for us," he said.

Longer-term margins could swell along with the increasing market size.

"[AI search is] reinforcing confidence that [Doximity's] elevated AI investments will ultimately support attractive long-term margins," Michael Cherney at Leerink Partnerships wrote to clients on Thursday.

While great news for Doximity, the huge upswing the in the stock on Friday morning is bad for anybody who is shorting it.

About 17% of shares available for trading were sold short heading into the earnings results, according to FactSet. As those short sellers are forced to unwind those positions, it likely added fuel to Doximity's surge.

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2027 first quarter ended June 30, 2026. “We're proud that our clinical AI assistant, Doximity Ask, was the top-performing U.S.-based model in the NOHARM benchmark while we delivered another quarter of record engagement,” said Jeff Tangney, co-founder and CEO of Doximity. "In Q1 we had accelerated revenue growth along with workflow active.

Digital health care company Doximity Inc (NYSE:DOCS) reported first-quarter financial results Thursday after market close.

Here are the key highlights and why the stock is soaring after hours.

Doximity Q1 EarningsDoximity reported first-quarter revenue of $156.6 million, up 7% year-over-year. The revenue total beat the Street consensus estimate of $151.7 million according to data from Benzinga Pro.

The company reported earnings of 29 cents per share, narrowly missing a Street estimate of 30 cents per share.

Adjusted EBITDA was $74.8 million in the quarter, with a margin of 48%.

"We’re proud that our clinical AI assistant, Doximity Ask, was the top-performing U.S.-based model in the NOHARM benchmark while we delivered another quarter of record engagement," Doximity CEO Jeff Tangney said.

The CEO said the company had workflow active prescriber growth of more than 30% year-over-year and AI search query growth of more than 25% quarter-over-quarter.

What’s Next for DoximityThe company is guiding for second-quarter revenue to be in a range of $170 million to $171 million. The Street estimate is $171.95 million according to Benzinga Pro.

For the full fiscal year, the company raised its revenue guidance to a range of $671 million to $681 million. The previous range was $664 million to $676 million. The Street estimate for full-year revenue is currently $670.29 million.

The company expects full-year adjusted EBITDA in a range of $309 million to $329 million.

After a mixed quarter with strong revenue growth and a narrow earnings per share miss, investors are sending shares higher on raised guidance for the full year, which is above analyst estimates.

Doximity Stock Price ActionDoximity stock is up 72% to $35.55 in after-hours trading Thursday versus a 52-week trading range of $17.15 to $76.51.

Photo: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Doximity (DOCS - Free Report) reported $156.62 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 7.3%. EPS of $0.29 for the same period compares to $0.36 a year ago.

The reported revenue represents a surprise of +3.24% over the Zacks Consensus Estimate of $151.7 million. With the consensus EPS estimate being $0.30, the EPS surprise was -3.33%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Doximity performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Number of customers with at least $500,000 of revenue: 127 versus the two-analyst average estimate of 129.Revenues- Other: $10.32 million versus $9.04 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +28.4% change.Revenues- Subscription: $146.3 million compared to the $142.87 million average estimate based on three analysts. The reported number represents a change of +6.1% year over year.View all Key Company Metrics for Doximity here>>>

Shares of Doximity have returned -0.3% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Doximity (DOCS - Free Report) closed at $20.99 in the latest trading session, marking a +2.79% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.02%. Elsewhere, the Dow saw an upswing of 0.51%, while the tech-heavy Nasdaq depreciated by 0.18%.

The medical social networking site's shares have seen a decrease of 2.2% over the last month, not keeping up with the Medical sector's gain of 3.09% and the S&P 500's gain of 0.77%.

The investment community will be closely monitoring the performance of Doximity in its forthcoming earnings report. The company is scheduled to release its earnings on August 6, 2026. The company is predicted to post an EPS of $0.3, indicating a 16.67% decline compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $151.7 million, showing a 3.97% escalation compared to the year-ago quarter.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $1.42 per share and a revenue of $670.18 million, indicating changes of -6.58% and +3.93%, respectively, from the former year.

It is also important to note the recent changes to analyst estimates for Doximity. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Doximity currently has a Zacks Rank of #3 (Hold).

Looking at its valuation, Doximity is holding a Forward P/E ratio of 14.4. This valuation marks a discount compared to its industry average Forward P/E of 23.92.

Also, we should mention that DOCS has a PEG ratio of 3.75. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. DOCS's industry had an average PEG ratio of 2.89 as of yesterday's close.

The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 80, finds itself in the top 33% echelons of all 250+ industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

Doximity (NYSE:DOCS – Get Free Report) and OBOOK (NASDAQ:OWLS – Get Free Report) are both services companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Analyst Recommendations This is a summary of current ratings for Doximity and OBOOK, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Doximity 3 13 6 2 2.29 OBOOK 1 0 1 0 2.00 Doximity presently has a consensus target price of $29.33, suggesting a potential upside of 39.73%. OBOOK has a consensus target price of $11.00, suggesting a potential upside of 101.83%. Given OBOOK’s higher possible upside, analysts clearly believe OBOOK is more favorable than Doximity.

Profitability This table compares Doximity and OBOOK’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Doximity 30.40% 20.40% 17.43% OBOOK N/A N/A N/A Institutional and Insider Ownership 87.2% of Doximity shares are owned by institutional investors. 31.8% of Doximity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation This table compares Doximity and OBOOK”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Doximity $644.86 million 5.95 $196.05 million $0.99 21.21 OBOOK $7.86 million 61.25 -$31.85 million N/A N/A Doximity has higher revenue and earnings than OBOOK.

Summary Doximity beats OBOOK on 10 of the 12 factors compared between the two stocks.

About Doximity (Get Free Report)

Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company’s cloud-based platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical companies and health systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.

About OBOOK (Get Free Report)

Our mission is to use blockchain technology to provide businesses with more reliable and transparent data management, to reinvent global flow of funds for businesses and consumers and to lead the digital transformation of business operations. We believe in the power of blockchain technology and have focused on leveraging it to optimize and in some cases transform the way enterprises operate. Established in 2010 in Taiwan, we operate as the OwlTing Group and have delivered solutions to various industries and are expanding actively into multiple markets including the United States, Japan, Singapore, Hong Kong, Malaysia and Thailand, as well as jurisdictions in South America and the EU. Through our e-commerce, hospitality and payments offerings, we are committed to serving businesses and individuals whose commercial activities involve cross-border transactions. From our earliest days with our product OwlTing Market™, our e-commerce platform that was designed to connect local Taiwanese farmers and merchants with their customers, we have worked closely with the merchants on our platform and come to understand their business pain points. Our OwlTing Blockchain Services™ emerged from such business understanding, and we have aimed to build a blockchain traceability solution that empowers organic farmers with better transparency of their business and operations, which can be extended to other use cases. By building our expertise in blockchain ledger transaction models, we concluded that the prevention of double spending with the use of timestamps and proof of work could also be utilized in the hospitality industry, which faces the need to address double-booking problems. We thus expanded into the hospitality sector in 2018 by offering innovative solutions to hotels and other hospitality industry customers through our platforms, including the OwlNest™ hotel property management system, or PMS, that leverages blockchain technology to prevent double bookings. We also launched the OwlJourney™, an online travel agency, or OTA, platform that benefits from accurate real-time inventory data from integration with OwlNest’s inventory system, to empower travel service providers with optimized efficiencies. In addition, our OwlTing Experiences™, also an OTA, focuses on offering curated local activity and tour options for lodging guests, enriching their travel experiences beyond accommodations. As we further developed our presence in the hospitality industry, we also gained a first-hand understanding of the challenges of cross-border payments faced by our hospitality clients. We saw the issues faced by our hospitality clients and their two most prominent pain points in the payment process: high processing costs from cross-border transactions and delayed settlement from the payers, including large OTAs. In response, we launched OwlPay™ in 2023 intending to enable businesses in the hospitality sector and beyond to use stablecoins and/or fiat currency in payouts to global suppliers. OwlPay is an application programming interface, or API, based payment suite with secure, real-time and cost-effective one-stop payment solutions covering a range of services from payment gateway to business payout. Using blockchain technology and developer-friendly APIs for integration, OwlPay aims to payments for both businesses and consumers. OwlPay is a full-stack payment service suite that supports multiple payout settlement routes, not only in fiat currency but also in stablecoin USD Coin (“USDC”) backed by U.S. dollar-denominated assets, through various product offerings. We currently offer various solutions for both platform solutions that provide user interfaces to our end users and infrastructure solutions that support third-party providers, through OwlPay Payment, OwlPay Wallet Pro and OwlPay Harbor within the OwlPay suite. OwlPay Payment provides user interfaces that offer services ranging from payment gateway to various payout solutions in stablecoin and fiat currencies. OwlPay Wallet Pro is a platform product that provides a hosted wallet for business customers and an unhosted wallet for individual users, supporting stablecoin on/off-ramp services and enabling both business and individual customers to receive and send money both domestically and internationally within minutes, with stablecoins over the public blockchain ledgers Ethereum, Avalanche, Polygon, Optimism, Arbitrum and Stellar. In addition, OwlPay Wallet Pro recently introduced a digital gift card service in the U.S., allowing users to purchase and redeem gift cards directly with USDC, thereby extending the everyday utility of stablecoins in retail and consumer payments. We also provide an infrastructure solution: OwlPay Harbor—our proprietary API packages—provides the functionalities of payment gateway collection of customers fund via stablecoins, on/off-ramp between fiat currencies and stablecoins, cross-chain transactions between USDC across different blockchains, and payout capabilities, empowering third-party wallet providers, financial institutions, and platform operators requiring cross-border payment solutions to offer stablecoin-based payment gateways, on/off-ramp services, cross-chain transactions, and payouts to their end users by leveraging our infrastructure. We currently provide these API packages across multiple blockchains, including EVM-compatible networks, the Solana network, and the Stellar network, where we serve as a “Stellar Anchor”. We also plan to provide Wallet-as-a-Service (WaaS), allowing enterprises to customize and deploy wallets for their end users. For our end customers holding a wallet with our OwlPay Wallet Pro, we provide the on/off-ramp services to facilitate conversion between USDCs and U.S. dollars, both directly interfacing our products and through our third-party collaborators and service providers, MoneyGram and MoonPay. For business customers that wish to leverage USDC, we offer on/off-ramping services via wire transfers and automated clearing houses (“ACH”). For individual customers, we offer on/off-ramping services via wire transfers and ACH, as well as via cash and credit card leveraging our collaborations with MoneyGram and MoonPay, respectively. We plan to further expand our on/off-ramping capabilities via debit cards using VISA Direct. Such conversion services are also available to customers of third-party wallet providers or financial institutions using OwlPay Harbor, our proprietary API package that enables third-party users to access our conversion capabilities, between fiat currencies and stablecoins, as well as between USDC across different blockchains (which also integrates stablecoin-based payment gateway solutions and payout capabilities). All transactions are within standard security and compliance infrastructure on par with a traditional financial institution. To make transactions more convenient for our OwlPay Wallet Pro customers on supported blockchains, we handle the payment of the gas fees (which are transaction fees paid for executing transactions on a blockchain network, typically paid in the digital asset native to such blockchain network) incurred on these blockchains on behalf of our OwlPay Wallet Pro customers for certain types of customers and transactions, so that these customers do not need to hold the native digital assets of the transaction chain. We currently support OwlPay Wallet Pro’s customers to send, receive and hold USDC, EURC, ZUSD, and GYEN and the conversion between USD and USDC. Additionally, for individual customers, we also support sending, receiving and holding native digital assets. OwlPay Wallet Pro recently introduced a digital gift card service in the U.S., allowing users to purchase and redeem gift cards directly with USDC, thereby extending the everyday utility of stablecoins in retail and consumer payments. OwlPay’s customers are currently able to access various fiat currency and USDC payment options and perform these payment transactions within OwlPay suite. We plan to expand OwlPay Wallet Pro services to support more blockchains, including Base, and plan to diversify our stablecoin offering to enable a broader set of conversion corridors between fiat currencies and stablecoins, as well as to facilitate foreign exchange transactions using stablecoins in the future. We have also rolled out our OwlPay Harbor services to other participants in the digital asset economy and payment industry, including serving as a “Stellar Anchor” for on/off-ramping USDC on Stellar to third parties on the Stellar Network and supporting EVM-compatible blockchains and Solana. OwlPay is designed to simplify backend financial operations and cross-border transactions. For potential business clients without in-house technical teams to support system integration but requiring payment gateway and cross-border payout services, we offer OwlPay Payment—an user interface solution that seamlessly connects with their bank accounts/wallets, facilitating vendor and order management, mass payouts, real-time exchanges and automated payment processes using fiat currency and USDC. The payout transactions are signed using hardware security module technology, a specialized security device used to manage, process and store digital keys securely, in order to ensure cryptographic operations are performed within a tamper-resistant environment. All of these features enhance the payment experience for businesses, especially SMEs that have limited scale of operations but still require efficient cross-border payment solutions. Beyond business clients, we expect to further develop and release services for individual customers that would integrate payment services offered by card networks, such as VISA Direct, to provide our individual customers a convenient way to send funds from a bank or card account to another party’s card or bank account within the same card network. Within the OwlPay suite, our customers can access various fiat currency and USDC payment options and seamlessly perform transactions through different solutions, and we believe we are an early mover to provide the one-stop service framework which enables businesses to collect payments from end-users and make payments to vendors, with the flexibility to settle transactions in either fiat currency or USDC and enables individuals a simpler, more convenient and faster way to perform cross-border transactions and remittances. According to CB Insights’ latest Stablecoin Market Map, OwlTing is ranked among the top 2 global players in the “Enterprise & B2B” category, earning a high Mosaic score of 832—underscoring its leadership in blockchain-powered financial infrastructure for businesses. OwlPay for its business customers supports B2B stablecoin transactions via a hosted wallet infrastructure and a comprehensive suite of services, including stablecoin payment gateway services, on/off-ramp capabilities, cross-chain transfers and payout services. These services enable key use cases such as e-commerce payments, cross-border remittances, payroll, and treasury management. The Mosaic score—CB Insights’ proprietary metric evaluating market opportunity, momentum, and financial strength—highlights OwlTing’s strong market positioning and growth potential in the enterprise stablecoin ecosystem. OwlPay continues to build multi-jurisdictional capabilities and aims to expand its service offerings internationally. For example, we currently hold money transmitter licenses, or MTLs, in 35 states in the United States and the Virtual Asset Service Provider, or VASP, registration in Poland, and the Electronic Payment Instrument Service Provider, or EPISP, registration in Japan. We are in the process of applying for MTLs in remaining states in the United States, an Electronic Money Institution (EMI) license in the EU, a fund transfer service license and a stablecoin license in Japan, a major payment institution license in Singapore and a money service operator license in Hong Kong; and we expect to upgrade the qualification as a Crypto Asset Service Provider, or CASP, under Markets in Crypto-Assets Regulation (MiCAR) in the EU. We also plan to further expand to Brazil, Argentina and other markets in South America where we could provide virtual asset services without being subject to licensing requirements. We believe our payment business powered by blockchain technology will be the most significant driver of our future business expansion plans. Our OwlPay services have historically been focused on processing transactions in fiat currencies, and no revenues for the years ended December 31, 2023 and December 31, 2024 were generated from OwlPay Harbor and OwlPay Wallet Pro. As we continue to roll out OwlPay Harbor and OwlPay Wallet Pro and expect market adoption of stablecoins to increase, we believe OwlPay Harbor and OwlPay Wallet Pro would enhance the breadth of our OwlPay services and strengthen our market position in digital asset payment solutions. We further believe our expansion into new products and markets from our current customer-centric businesses will enable us to capture cross-selling opportunities with our existing relationships in the e-commerce and hospitality industries, and to grow into a comprehensive cross-border payment solution suite and business ecosystem. For the year ended December 31, 2024, our company’s total revenue was comprised of our operations in the following main business segments: (i) Payments contributed to 53% of our total revenue; (ii) Hospitality (which include software services and platform services) contributed to 37% of our total revenue; and (iii) E-commerce contributed to 10% of our total revenue. Obook Holdings Inc. is located in Taipei City, Taiwan, Republic of China.

Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways DOCS is expanding AI with rising physician use and early AI Search contracts with top-20 pharma companies.Doximity's Clinical AI Suite now serves 140 health systems, supporting retention and cross-selling.DOCS expects AI investment to trim margins as regulatory reviews delay meaningful revenue contribution. Doximity (DOCS - Free Report) is entering a pivotal phase as it accelerates investments in artificial intelligence to expand beyond its core physician engagement platform. While robust physician adoption, growing enterprise AI deployments and exceptional cash generation strengthen its long-term outlook, a sluggish pharma advertising market, rising AI investments and commercialization risks could temper near-term financial performance.

Shares of this Zacks Rank #3 (Hold) company have lost 49.8% so far this year compared with the industry's 5.6% decline and the S&P 500 Index’s 10.9% rise.

Doximity, with a market capitalization of $4.07 billion, is a global specialty medical device company.

DOCS’ bottom line is estimated to improve 3.8% over the next five years. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.99%.

Image Source: Zacks Investment Research

What's Driving DOCS’ Performance?AI Platform Is Rapidly Becoming Doximity's Next Major Growth Engine: Doximity is positioning artificial intelligence as its largest long-term monetization opportunity. Since acquiring Pathway, AI Search and AI Scribe users have tripled, while nearly half of all active prescribers now use the company's AI tools.

Management has already signed its first AI Search contracts with top-20 pharmaceutical companies and believes AI Search alone represents a multibillion-dollar incremental addressable market beyond its existing pharma advertising business. The combination of physician engagement, hospital adoption and early customer interest suggests Doximity is building a differentiated AI ecosystem that could materially expand revenues over the next several years rather than simply enhancing existing products.

Deepening Health System Integration: Doximity's growing integration into hospital workflows is making its platform increasingly indispensable to physicians. Nearly half of all U.S. doctors now work at health systems using Doximity's workflow or scheduling tools, while 140 health systems, including seven of the top 20 U.S. hospitals, have adopted its Clinical AI Suite.

Management emphasized that more than 250,000 prescribers now access AI capabilities through HIPAA-compliant enterprise deployments, creating a significant barrier for competitors. As hospitals increasingly prioritize secure AI environments over public AI tools, Doximity's trusted infrastructure, physician network and enterprise relationships should support higher customer retention and expanding cross-selling opportunities across workflow, telehealth and AI solutions.

Record Physician Engagement: Doximity continues to strengthen the core asset underpinning its business — physician engagement. Workflow usage increased approximately 30% year over year, reaching more than 800,000 quarterly active prescribers, representing one of the strongest engagement accelerations in the company's history. AI usage is growing even faster, with users nearly doubling their monthly query activity since January.

Higher engagement not only strengthens customer loyalty but also increases the value of Doximity's advertising, workflow and AI offerings to pharmaceutical companies and health systems. Management believes sustained engagement growth will eventually translate into stronger revenue expansion, particularly as new AI-powered commercial products become more widely adopted across its physician network.

What’s Weighing on DOCS Stock?Core Pharma Advertising Market Remains Weak: The biggest near-term challenge for Doximity remains the soft healthcare professional (HCP) digital advertising market. Management acknowledged continued policy uncertainty, macroeconomic risks and shorter pharmaceutical budgeting cycles, causing many customers to delay spending commitments and favor shorter-duration contracts.

The company expects the overall HCP digital advertising market to grow only around 5% or less during fiscal 2027, significantly below historical levels. Although Doximity continues to outperform many peers, sluggish industry spending limits visibility and reduces opportunities for traditional advertising growth. Until pharmaceutical companies regain confidence and commit to longer-term marketing budgets, revenue acceleration is likely to remain constrained.

AI Monetization Will Pressure Margins: While AI represents Doximity's largest long-term opportunity, management expects fiscal 2027 to be an investment year rather than a significant earnings contributor. The company plans to substantially increase spending on AI compute, engineering talent, brand marketing, and product development, resulting in adjusted EBITDA margins declining from 55% in fiscal 2026 to approximately 49% in fiscal 2027.

Management also expects minimal AI revenue contribution during the first half because regulatory reviews and customer implementation timelines will delay commercialization. Consequently, the company could face a period of elevated expenses without commensurate revenue growth, increasing execution risk if AI adoption progresses more slowly than anticipated.

Commercial Success Depends on Regulatory and Customer Adoption of AI: Although customer interest in AI Search appears strong, commercialization remains at a very early stage. Management acknowledged that pharmaceutical companies must complete extensive medical, legal and regulatory reviews before campaigns can be deployed, creating longer implementation timelines than traditional advertising products.

Because Doximity launched the commercial offering only recently, management expects most of the financial benefits to materialize in the second half of fiscal 2027. Delays in regulatory approvals, customer onboarding, or campaign execution could defer revenue recognition. Given management's expectation that AI Search will become a major future growth driver, slower-than-expected commercialization would likely weigh on investor expectations.

Estimate TrendThe Zacks Consensus Estimate for fiscal 2027 revenues is pegged at $670.2 million, implying growth of 3.9% from the year-ago reported figure. The consensus mark for adjusted EPS is pinned at $1.39, indicating a decline of 8.6% from the previous year’s recorded level.

In the past 60 days, DOCS’ earnings estimate for fiscal 2027 has remained stable.

Stocks to ConsiderSome better-ranked stocks from the broader medical space are Alcon (ALC - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Alcon reported first-quarter 2026 earnings per share of 85 cents, which beat the Zacks Consensus Estimate by 6.3%. Revenues of $2.69 billion surpassed the Zacks Consensus Estimate by 0.3%.

Alcon has an estimated long-term earnings growth rate of 11.5%. ALC’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 3.66%.

Intuitive Surgical reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

Intuitive Surgical has an estimated long-term earnings growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.

Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.3%.

-

Doximity Ask outranked OpenEvidence, GPT-5.6 Sol, Claude Fable 5, and other frontier models

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that Doximity Ask, its HIPAA-compliant clinical AI platform, outperformed leading frontier AI models in the NOHARM (Numerous Options Harm Assessment for Risk in Medicine) benchmark, one of the most comprehensive independent evaluations of clinical AI safety to date.

The study, conducted by ARISE, a clinical AI research team led by physicians from Stanford and Harvard Medical Schools, evaluated how AI models perform when researchers prompted them with simulated patient cases.

Doximity Ask ranked first among all AI systems evaluated on the study's real-world clinical sample, the portion of the benchmark that most closely mirrors how physicians use these tools in practice. Across the broader automated evaluation, purpose-built clinical AI systems outperformed general-purpose frontier models by a wide margin.

Why Doximity Ask Outperformed

Doximity Ask is a HIPAA-compliant AI assistant built specifically for clinical workflows.

Our performance traces directly to our investment in physician authorship at scale. Through our PeerCheck™ program, more than 11,000 cited physician experts have evaluated and improved Doximity Ask outputs.

"We have long believed that the path to trustworthy healthcare AI runs through physicians, not around them," said Dr. Louis-Antoine Mullie, Head of Medical AI at Doximity. "Continuous physician review isn't a differentiator. It's a requirement. This result reinforces the importance of combining advanced AI systems with rigorous clinical oversight and independent safety evaluations like NOHARM."

Doximity's Clinical AI Suite, including Ask, has been reviewed, approved, and deployed across more than 150 health systems, including eight of the nation's top 20 hospitals.

The platform includes end-to-end encryption, role-based access controls, audit logging, and session isolation to help healthcare organizations deploy AI while maintaining enterprise-grade security and privacy standards.

To learn more about Doximity Ask, visit www.doximity.com.

Read more about the study methodology on the Doximity blog.

Notes to Editors:

For the full study, please click here. The chart on the left shows how the top U.S. models performed on F1 score, which balances precision and recall, before the cases and answers were made public. The chart on the right shows automated testing across more than 1,100 scenarios spanning 10 medical specialties. The benchmark was developed by more than 50 researchers with contributions from 29 board-certified physicians. About Doximity

Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. With new AI-powered clinical reference and search capabilities, Doximity also helps doctors access trusted, peer-reviewed information and medical literature. Doximity's mission is to help doctors be more productive so they can provide better care for their patients.

More News From Doximity

Back to Newsroom

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Doximity Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders.

If you currently own Doximity stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

Why Your Participation Matters:

Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

Bank of America Securities (BofA) on Monday downgraded Doximity Inc. (NYSE:DOCS), citing limited clarity on the trajectory of revenue/margins.

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Doximity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 13, 2026, Doximity issued a press release announcing its fourth quarter and fiscal year 2026 financial results.  Among other items, Doximity guided for full-year revenue in the range of $664 million to $676 million, compared to estimates of $687.04 million, and adjusted EBITDA of $323 million to $335 million.  Doximity's management highlighted AI cost pressure, with the Company's vice president of investor relations citing gross margin impact "driven by AI compute costs" and CEO Jeff Tangney warning that higher AI investment will "weigh on near-term margins." 

On this news, Doximity's stock price fell $5.38 per share, or 23%, to close at $18.01 per share on May 14, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Doximity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 13, 2026, Doximity issued a press release announcing its fourth quarter and fiscal year 2026 financial results.  Among other items, Doximity guided for full-year revenue in the range of $664 million to $676 million, compared to estimates of $687.04 million, and adjusted EBITDA of $323 million to $335 million.  Doximity’s management highlighted AI cost pressure, with the Company’s vice president of investor relations citing gross margin impact “driven by AI compute costs” and CEO Jeff Tangney warning that higher AI investment will “weigh on near-term margins.” 

On this news, Doximity’s stock price fell $5.38 per share, or 23%, to close at $18.01 per share on May 14, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Doximity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 13, 2026, Doximity issued a press release announcing its fourth quarter and fiscal year 2026 financial results.  Among other items, Doximity guided for full-year revenue in the range of $664 million to $676 million, compared to estimates of $687.04 million, and adjusted EBITDA of $323 million to $335 million.  Doximity's management highlighted AI cost pressure, with the Company's vice president of investor relations citing gross margin impact "driven by AI compute costs" and CEO Jeff Tangney warning that higher AI investment will "weigh on near-term margins." 

On this news, Doximity's stock price fell $5.38 per share, or 23%, to close at $18.01 per share on May 14, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP